Molbio Diagnostics Limited is a molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of point-of-care (POC) diagnostic solutions. Its proprietary Truenat platform enables rapid and accurate molecular testing for infectious diseases at hospitals, laboratories, and decentralized healthcare settings.
The company offers Truelab analyzers, Trueprep devices, Truenat test kits, reagents, consumables, and software. As of March 31, 2026, it had 43 diagnostic assays covering 30 diseases and sold 2,524 diagnostic devices and 17.56 million test kits during Fiscal 2026.
Beyond molecular diagnostics, the company also offers digital radiology, medical imaging, and digital pathology solutions through its subsidiaries, expanding its presence across the healthcare diagnostics ecosystem.
Research and development are carried out through Bigtec Private Limited, with a DSIR-recognized R&D centre. As of March 31, 2026, the company had 153 R&D personnel and a portfolio of 207 granted patents (16 in India and 191 overseas).
Molbio operates multiple manufacturing facilities across Goa, Bengaluru, Visakhapatnam, and Pune. The company serves government healthcare programmes, hospitals, diagnostic laboratories, research institutions, and international healthcare organizations in over 90 countries.
As of March 31, 2026, the company had 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.
Molbio Diagnostics IPO – Details
| IPO Opening Date | 10 August 2026 |
| IPO Closing Date | 12 August 2026 |
| Issue Type | Book Built Issue IPO |
| Issue Size | Total Issue Size: 1,16,46,246 Shares Worth ₹939.85 Crore Fresh Issue: 24,80,246 Shares Worth ₹200.16 Crore Offer For Sale: 91,66,000 Shares Worth ₹739.70 Crore |
| Face Value | ₹1 per equity share |
| IPO Price | ₹768 – ₹807 per share |
| Market Lot | 18 Shares |
| Min Order | 18 Shares [1 Lot] |
| Listing At | BSE, NSE |
| Register | Kfin Technologies Ltd. |
| QIB Shares Offered | 50% |
| NII (HNI) Shares Offered | 15% |
| Retail Shares Offered | 35% |
Molbio Diagnostics IPO – Date Schedule
| IPO Open Date | 10 August 2026 |
| IPO Close Date | 12 August 2026 |
| Basis of Allotment | 13 August 2026 |
| Initiation of Refund | 14 August 2026 |
| Credit of Shares to Demat Account | 14 August 2026 |
| IPO Listing Date | 17 August 2026 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 12, 2026 |
Molbio Diagnostics IPO – Lots Size & Price
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| S-HNI (Max) | 68 | 1224 | ₹9,87,768 |
| B-HNI (Min) | 69 | 1242 | ₹10,02,294 |
Competitive Strength
- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits.
- Global presence across 90+ countries with strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
Company Promoters
- Chandrasekhar Bhaskaran Nair
- Exxora Trading LLP
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Sriram Natarajan
Company Financials
| Particulars | Total Revenue | Total Expense | Profit After Tax | Total Borrowing |
|---|---|---|---|---|
| 31 March 2024 | ₹840.66 Cr | ₹657.83 Cr | ₹83.54 Cr | ₹174.58 Cr |
| 31 March 2025 | ₹1,027.94 Cr | ₹820.41 Cr | ₹138.58 Cr | ₹123.16 Cr |
| 31 March 2026 | ₹1,455.17 Cr | ₹1221.35 Cr | ₹164.14 Cr | ₹412.64 Cr |
Key Performance Indicator
| KPI | Values (Mar 31, 2026) |
|---|---|
| ROE | 15.59% |
| ROCE | 17.55% |
| RoNW | 14.55% |
| PAT Margin | 11.28% |
| EBITDA Margin | 22.56% |
| NAV | 101.51 |
| Pre IPO | Post IPO | |
| EPS (₹) | 14.56 | – |
| P/E (x) | – | – |
Object Of The Issue
| Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|
| Funding capital expenditure towards the setting up of infrastructure for the research and development facility, Center of Excellence, and connected office space. | ₹125.12 |
| Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | ₹80.81 |
| General Corporate Purposes. |
Molbio Diagnostics IPO Peer Comparison
| S. No. | Face Value (₹) | Company Name | P/E Ratio |
|---|---|---|---|
| 1 | 5 | Poly Medicure Limited | 52.61 |
| 2 | 10 | Dr. Lal Pathlabs Limited | 62.20 |
| 3 | 2 | Metropolis Healthcare Limited | 63.72 |
| 4 | 1 | Vijaya Diagnostics Centre Limited | 81.02 |
✅Strengths
- Proprietary Truenat molecular diagnostics platform.
- Strong R&D with a large patent portfolio.
- Recurring revenue from diagnostic test kits.
- Presence in 90+ countries with diversified products.
- Experienced management and healthcare expertise.
⚠️Risks
- High dependence on government healthcare programs.
- Growth depends on adoption of the Truenat platform.
- Supply chain disruptions may affect production.
- High working capital requirements.
- Intense competition in the diagnostics industry.
Molbio Diagnostics IPO Promoter Holding
| Pre-Issue Share Holding | 46.65% |
| Post Issue Share Holding | 43.01% |
Molbio Diagnostics IPO Prospectus
Company Contact Information
| Molbio Diagnostics Limited Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722 Phone: 8326724888 Email: investors@molbiodiagnostics.com Website: https://www.molbiodiagnostics.com/ |
Molbio Diagnostics IPO Registrar
| Kfin Technologies Ltd. Phone: 040-79615565 Email: molbio.ipo@kfintech.com Website: https://ipostatus.kfintech.com/ |
Molbio Diagnostics IPO Lead Manager(s)
| 1. IIFL Capital Services Limited 2. Jefferies India Private Limited 3. Kotak Mahindra Capital Company Limited 4. Motilal Oswal Investment Advisors Limited |
Molbio Diagnostics IPO FAQs
| What is the Molbio Diagnostics IPO? Molbio Diagnostics IPO is a main-board IPO. The issue is priced at ₹768 to ₹807 per equity share. The IPO is to be listed on the BSE & NSE. |
| When will the Molbio Diagnostics IPO open? The IPO is to open on 10 August 2026 for QIB, NII, and Retail Investors. |
| What is Molbio Diagnostics IPO investors’ portion? The investors’ portion is QIB – 50%, NII – 15%, and Retail – 35%. |
| What is the Molbio Diagnostics IPO Size? Molbio Diagnostics IPO size is ₹939.70 Crore. |
| What are the Molbio Diagnostics IPO Minimum and maximum lot sizes for Retail? The minimum bid is 18 Shares with ₹14,526, while the maximum bid is 234 Shares with ₹1,88,838. |
| What is the Molbio Diagnostics IPO Allotment Date? Molbio Diagnostics IPO allotment date is 13 August 2026. |
| What is the Molbio Diagnostics IPOO Listing Date? Molbio Diagnostics IPO listing date is 17 August 2026. The IPO is to be listed on the BSE and the NSE. |
